TD Cowen Cuts GoodRx (NASDAQ:GDRX) Price Target to $6.00

GoodRx (NASDAQ:GDRX) had its price objective reduced by research analysts at TD Cowen from $7.00 to $6.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen’s target price would indicate a potential upside of 99.00% from the company’s current price.

Other analysts have also issued reports about the stock. Weiss Ratings lowered shares of GoodRx from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. Raymond James Financial downgraded shares of GoodRx from a “strong-buy” rating to an “outperform” rating in a research report on Friday, August 8th. UBS Group lowered their price objective on shares of GoodRx from $4.25 to $4.00 and set a “neutral” rating on the stock in a research report on Thursday. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $6.00 price target on shares of GoodRx in a report on Monday, August 11th. Finally, Mizuho reduced their price objective on GoodRx from $5.00 to $4.00 and set a “neutral” rating for the company in a research note on Thursday. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $5.61.

GoodRx Stock Performance

Shares of GoodRx stock traded down $0.10 during trading on Monday, hitting $3.02. 936,275 shares of the stock were exchanged, compared to its average volume of 2,512,706. The company has a debt-to-equity ratio of 0.81, a quick ratio of 3.11 and a current ratio of 3.11. GoodRx has a 12 month low of $2.95 and a 12 month high of $5.81. The stock’s fifty day moving average is $4.02 and its 200 day moving average is $4.28. The stock has a market cap of $1.05 billion, a PE ratio of 33.50, a P/E/G ratio of 1.62 and a beta of 1.19.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The company had revenue of $196.03 million for the quarter, compared to the consensus estimate of $195.17 million. GoodRx had a return on equity of 9.73% and a net margin of 3.97%.The firm’s quarterly revenue was up .4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.08 earnings per share. GoodRx has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that GoodRx will post 0.13 EPS for the current year.

Insider Buying and Selling at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $4.00, for a total value of $95,084.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On GoodRx

A number of institutional investors have recently modified their holdings of GDRX. Raymond James Financial Inc. grew its stake in GoodRx by 54.6% in the 1st quarter. Raymond James Financial Inc. now owns 830,950 shares of the company’s stock valued at $3,664,000 after buying an additional 293,420 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in GoodRx by 20,956.5% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 14,529 shares of the company’s stock worth $64,000 after acquiring an additional 14,460 shares during the last quarter. Algert Global LLC bought a new stake in GoodRx during the first quarter valued at about $1,224,000. XTX Topco Ltd acquired a new stake in shares of GoodRx in the first quarter valued at about $315,000. Finally, EP Wealth Advisors LLC acquired a new stake in shares of GoodRx in the first quarter valued at about $69,000. Institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.